Stockscreener 앱 받기
1.11
5.93%
-0.07
시간 외 거래:
1.13
0.02
+1.80%
전일 마감가:
$1.18
열려 있는:
$1.16
하루 거래량:
2.10M
Relative Volume:
0.61
시가총액:
$246.29M
수익:
$95,000
순이익/손실:
$-327.27M
주가수익비율:
-0.5236
EPS:
-2.12
순현금흐름:
$-239.25M
1주 성능:
-11.90%
1개월 성능:
-16.54%
6개월 성능:
-34.71%
1년 성능:
-63.00%
1일 변동 폭
$1.05
$1.175
1주일 범위
$1.05
$1.28
52주 변동 폭
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
명칭
Allogene Therapeutics Inc
전화
(650) 457-2700
주소
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
ALLO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.11 | 261.82M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-05-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | 재개 | Oppenheimer | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-08-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-28 | 재확인 | B. Riley Securities | Buy |
| 2021-10-20 | 개시 | Cowen | Outperform |
| 2021-10-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | 재개 | Jefferies | Buy |
| 2021-05-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-14 | 개시 | B. Riley Securities | Buy |
| 2021-01-26 | 업그레이드 | Stifel | Hold → Buy |
| 2020-12-10 | 재개 | H.C. Wainwright | Buy |
| 2020-11-24 | 개시 | BofA Securities | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-06-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-19 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2020-05-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-04-13 | 개시 | SunTrust | Buy |
| 2020-03-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-24 | 개시 | Berenberg | Hold |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-05 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Neutral |
| 2019-05-23 | 개시 | Stifel | Hold |
| 2019-03-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
How sentiment analysis helps forecast Allogene Therapeutics Inc.July 2025 Analyst Calls & Free Fast Gain Swing Trade Alerts - newser.com
Why Allogene Therapeutics Inc. stock remains on watchlistsJuly 2025 Trends & Safe Capital Growth Plans - newser.com
Allogene to present pivotal trial design for lymphoma therapy at ASH - Investing.com Nigeria
Will Allogene Therapeutics Inc. stock deliver better than expected guidanceJuly 2025 Price Swings & Accurate Intraday Trading Signals - newser.com
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting - The Manila Times
Allogene to present pivotal trial design for lymphoma therapy at ASH By Investing.com - Investing.com South Africa
Will Allogene Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Intraday Action & AI Enhanced Execution Alerts - newser.com
Analyzing Allogene Therapeutics Inc. with multi timeframe chartsJuly 2025 Trends & Community Verified Trade Signals - newser.com
Using AI based signals to follow Allogene Therapeutics Inc.Profit Target & Free Growth Oriented Trading Recommendations - newser.com
Published on: 2025-11-02 23:31:58 - newser.com
Will breakout in Allogene Therapeutics Inc. lead to full recoveryWeekly Market Report & High Accuracy Investment Signals - newser.com
Chart based analysis of Allogene Therapeutics Inc. trends2025 Top Decliners & Daily Profit Focused Screening - newser.com
Using portfolio simulators with Allogene Therapeutics Inc. includedJuly 2025 Big Picture & Risk Managed Investment Entry Signals - newser.com
Price action breakdown for Allogene Therapeutics Inc.Earnings Overview Report & AI Powered Trade Plan Recommendations - newser.com
Risk adjusted return profile for Allogene Therapeutics Inc. analyzedPortfolio Growth Summary & AI Driven Stock Reports - newser.com
Applying Elliott Wave Theory to Allogene Therapeutics Inc.Quarterly Portfolio Report & Consistent Profit Trading Strategies - newser.com
Published on: 2025-11-02 02:58:33 - newser.com
What candlestick patterns are forming on Allogene Therapeutics Inc.Chart Signals & Community Trade Idea Sharing Platform - newser.com
Detecting support and resistance levels for Allogene Therapeutics Inc.2025 Major Catalysts & Technical Entry and Exit Tips - newser.com
Allogene Therapeutics (ALLO) to Release Quarterly Earnings on Thursday - MarketBeat
Allogene Therapeutics (NASDAQ: ALLO) sets Q3 2025 results; webcast at 2 p.m. PT - Stock Titan
Will Allogene Therapeutics Inc. stock beat EPS estimatesEarnings Risk Report & Free Growth Oriented Trading Recommendations - Fundação Cultural do Pará
Allogene Therapeutics Inc (ALLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):